GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Market Cap
Switch to:

Biogen (BUE:BIIB) Market Cap

: ARS10,213,822 Mil (As of Today)
View and export this data going back to 2019. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biogen's share price for the quarter that ended in Mar. 2023 was ARS8661. Biogen's Shares Outstanding (EOP) for the quarter that ended in Mar. 2023 was 145 Mil. Therefore, Biogen's market cap for the quarter that ended in Mar. 2023 was ARS1,254,113 Mil.

Biogen's quarterly market cap increased from Sep. 2022 (ARS916,344 Mil) to Dec. 2022 (ARS1,030,896 Mil) and increased from Dec. 2022 (ARS1,030,896 Mil) to Mar. 2023 (ARS1,254,113 Mil).

Biogen's annual market cap increased from Dec. 2020 (ARS407,746 Mil) to Dec. 2021 (ARS547,722 Mil) and increased from Dec. 2021 (ARS547,722 Mil) to Dec. 2022 (ARS1,030,896 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biogen's Enterprise Value for Today is ARS10,584,394 Mil.


Biogen Market Cap Historical Data

The historical data trend for Biogen's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 407,746.20 547,722.00 1,030,896.00

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Market Cap Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 457,250.00 587,188.80 916,344.00 1,030,896.00 1,254,112.80

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Market Cap Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Market Cap distribution charts can be found below:

* The bar in red indicates where Biogen's Market Cap falls in comparison to its industry or sector. The grey bar indicates the Market Cap's extreme value range as defined by GuruFocus.



Biogen Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Biogen's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=ARS7159*144
=ARS1,030,896

Biogen's Market Cap for the quarter that ended in Mar. 2023 is calculated as

Market Cap (Q: Mar. 2023 )=Share Price (Q: Mar. 2023 )*Shares Outstanding (EOP) (Q: Mar. 2023 )
=ARS8661*144.8
=ARS1,254,113

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (BUE:BIIB) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Biogen Market Cap Related Terms

Thank you for viewing the detailed overview of Biogen's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines